OBJECTIVE: This double-blind, sham-controlled trial investigated the effects of two daily tDCS sessions over a 5-day period in @entity13217 . METHOD: Twenty-four treatment-resistant @entity308 @entity1 received two daily sessions of active or sham anodal tDCS to the left prefrontal cortex (2mA, 10 sessions over 1week). @entity308 severity, @entity1155 and cognitive function were assessed. RESULTS: Active tDCS was not significantly superior to sham tDCS on the @entity3831 at week 4, as well as on the MADRS and SRRS scales, and on neuropsychological tests. Response rates were not significantly higher with active tDCS. tDCS was well tolerated, with mild adverse events limited to transient scalp discomfort. CONCLUSION: tDCS did not induce clinically relevant antidepressant effect in active and sham stimulation groups. There was no impact on psychomotor and neuropsychological functioning. SIGNIFICANCE: tDCS efficacy on specific symptom profiles in pharmacotherapy-resistant @entity308 is limited. The use of optimized stimulation protocol and longer period of follow up may valuably contribute to specify the place of tDCS in @entity13217 .

Pilot study of feasibility of the effect of treatment with tDCS in XXXX suffering from @entity13217 treated with escitalopram.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depressed', 'depression'] @entity3831 :: ('MESH:C537907', 'Disease') :: ['HDRS'] @entity13217 :: ('MESH:D061218', 'Disease') :: ['treatment-resistant depression'] @entity1155 :: ('MESH:D011596', 'Disease') :: ['psychomotor retardation']
@entity1 :: (9606,Species) :: ['patients']
